The price of common Chinese medicinal materials such as Atractylodes has suddenly skyrocketed, and it has risen to the point that merchants dare not take the goods casually, and even rumors have spread that Atractylodes has made a dream of making a fortune, what signal does this release?
Is there a mysterious capital force behind it that is maliciously disrupting the market? Is it maliciously opposing the state's policy of centralized procurement of traditional Chinese medicine? This question deserves in-depth study.
Recently, some merchants have publicly complained that the price of atractylodes has skyrocketed, and they don't dare to take the goods casually. The price of atractylodes is about 180 yuan per kilogram now, compared to only 18 yuan three years ago, and it has skyrocketed by 10 times in three years!
In fact, not only Atractylodes, but also very common Chinese medicinal materials such as Danpi and White Peony have also collectively opened a skyrocketing mode, and even niche medicinal materials such as cat's claw have jumped. This is unusual.
Because Chinese medicinal materials such as atractylodes and danpi are very common and have a wide range of uses. As far as Atractylodes atractylodes is concerned, because it has a number of medicinal functions such as tonifying the spleen and stomach, drying dampness and improving water, stopping perspiration and stabilizing the fetus, it is widely used in very common traditional Chinese medicine products such as compound Astragalus Spleen Oral Liquid, Huoxiang Zhengqi Water, Shenling Atractylodes Pills, etc., which is one of the important raw materials, and even many people will buy some Atractylodes usually stewed chicken, stewed soup or something.
Good guys, now the price is so crazy and skyrocketing, people don't dare to buy it, and they can't afford it. Merchants are even more miserable. Moreover, due to the soaring price of raw materials, the profits of downstream Chinese patent medicines have been under great pressure.
Especially in the context of the current traditional Chinese medicine products beginning to enter the national medical insurance centralized procurement, it has seriously affected the promotion of this policy of benefiting the people, what signal does this release? Is there any capital force behind the malicious layout? What are the possible reasons for the sudden surge in common Chinese medicinal materials such as Atractylodes?
In my opinion, this is absolutely inseparable from the deliberate layout of certain capital, even including foreign capital, deliberately hoarding, maliciously creating a phenomenon of skyrocketing prices to harvest the wealth of the Chinese people, and hindering the sinister intention of Chinese patent medicine to enter the national medical insurance centralized procurement.
As we all know, since last year, traditional Chinese medicine products have officially begun to enter the scope of national medical insurance centralized procurement. The national medical insurance centralized procurement policy is a people's livelihood policy that benefits the people and is a very important medical reform of the country in recent years.
After the centralized procurement of Western medicines is relatively mature, the centralized procurement of Chinese patent medicine products has been launched into the market since last year. Although there are not many varieties for the time being, it can be regarded as a pilot in the early stage, but if it goes well, it will definitely be widely spread like Western medicine. At that time, the current situation of the Chinese people who are difficult to see a doctor and expensive to buy medicine will be able to be significantly improved.
But it was at such a critical moment that a large-scale wildfire suddenly broke out in an important medicinal herb planting area in Guizhou last year. At the same time, due to the sudden surge in the price of common traditional Chinese medicine raw materials such as Atractylodes, some enterprises have been cut off from the supply of selected drugs in centralized procurement.
For example, at the end of last year, Shandong issued the "Announcement on Canceling the Qualifications of Four Enterprises and Including Them in the List of Violations". The reason is that the varieties of traditional Chinese medicine products selected by these four companies failed to ensure the supply according to the agreed purchase volume. Among these four companies, three of the pharmaceutical companies' traditional Chinese medicine products involve the raw material of atractylodes. Therefore, it can be clearly seen that because of the soaring prices of raw materials such as atractylodes, it has seriously affected the implementation of the national centralized procurement policy of traditional Chinese medicine products.
Some people may say that this may be a market-oriented behavior. The supply and demand situation has changed profoundly. If that's the case, that's normal. However, the key thing is that the demand for Chinese medicinal materials such as atractylodes has not suddenly broken through and widened, resulting in a significant increase in demand.
Therefore, a product like Atractylodes atractylodes cannot be the result of pure marketization, and there is definitely a boost from the power of mysterious capital behind it, which is hoarding and can create a phenomenon of shortage that you will miss if you don't buy it.
Moreover, because the raw materials of Chinese medicinal materials such as Atractylodes macrocephalus are agricultural and sideline products, it is difficult for the state to control them. Once the bubble bursts, many people who are attracted by the wealth-creating effect to hoard raw materials for traditional Chinese medicine are estimated to end up with chicken feathers and wealth harvested, which in turn will lead to social problems and hinder China's economic development.
In particular, it affects the implementation of the people's livelihood policy of medical insurance centralized procurement, so this problem is really worth being vigilant about.